ASCO GU 2020 Bladder Cancer

Viewing 1-20 of 43 articles

ASCO GU 2020: Results from BLASST-1 - Nivolumab, Gemcitabine, and Cisplatin in Muscle Invasive Bladder Cancer (MIBC) Undergoing Cystectomy.

ASCO GU 2020: Combining Chemotherapy with Novel Agents, Opportunities, and Challenges.

ASCO GU 2020: (NEO-BLADE) Phase II Randomized Placebo-Controlled Neoadjuvant Trial of Nintedanib or Placebo with Gemcitabine and Cisplatin in Locally Advanced Muscle Invasive Bladder Cancer

ASCO GU 2020: Results from ATLAS, a Phase 2, Open-Label Trial: Rucaparib for Recurrent, Locally Advanced or Metastatic Urothelial Carcinoma

ASCO GU 2020: The Efficacy of Two Cycles of Neoadjuvant Chemotherapy for Upper Tract Urothelial Carcinoma Patients.

ASCO GU 2020: Sequencing Chemotherapy and Surgery in Upper Tract Urothelial Cancers

ASCO GU 2020: Replacing TURBT with mpMRI for Staging MIBC: Pilot Data from the BladderPath study

ASCO GU 2020: Germline DNA Copy Number Polymorphism to Predict the Efficacy of BCG Therapy for Non-Muscle Invasive Bladder Cancer

ASCO GU 2020: Randomized Phase III trial for Treatment of Muscle-Invasive Urothelial Bladder Cancer: Preliminary Results of the GETUG/AFU V05 VESPER Trial on Toxicity and Pathological Responses

ASCO GU 2020: Enfortumab Vedotin Plus Pembrolizumab for Locally Advanced or Metastatic Urothelial Carcinoma - Preliminary Durability Results from Study EV-103

ASCO GU 2020: Risk Stratification and Management of High-Risk Muscle-Invasive Urothelial Carcinoma: Subtyping of High-risk Muscle Invasive Urothelial Carcinoma

ASCO GU 2020: Opportunities and Limitations of Genomics in Everyday Practice: Circulating Tumor DNA (ctDNA)

ASCO GU 2020: Practicing Beyond Clinical Trial Data: Real-World Challenges in Urothelial Carcinoma

ASCO GU 2020: Risk Stratification and Management of High-Risk Muscle-Invasive Urothelial Carcinoma: Adjuvant Options in High-Risk Disease After Primary Intervention

ASCO GU 2020: Circulating Tumor Cells: Opportunities in Muscle Invasive Bladder Cancer

ASCO GU 2020: Adjuvant Options in High-Risk Muscle Invasive Bladder Cancer After Primary Intervention

ASCO GU 2020: Medical Oncology Perspective - Best of Journals: Urothelial Carcinoma

ASCO GU 2020: Risk Stratification and Management of High-Risk Muscle Invasive Urothelial Carcinoma: Circulating Tumor DNA

ASCO GU 2020: Adjuvant Options in High-Risk Disease After Primary Intervention

ASCO GU 2020: Upper Tract Disease: Topical Therapy, Systemic Therapy

1
2
3